FrancophonIA/ELRC3.0 huggingface dataset:
English: Urinary void volume (ml) Baseline
Estonian: Põie tühjendamismaht (ml) Ravieelne
English: Rash, dry skin, rash pruritic
Estonian: Lööve, naha kuivus, kihelev lööve
English: Dizziness
Estonian: − ärevus
English: Figure C:
Estonian: Joonis C.
English: Your urge incontinence may return and you may have increased urinary frequency if you decide to stop using the patch.
Estonian: Kui te otsustate plaastri kasutamise lõpetada, võib teie tunginkontinents tagasi tulla ja urineerimisvajadus sageneda.
English: Dry mouth, constipation, diarrhoea, nausea, abdominal pain
Estonian: Suukuivus, kõhukinnisus, kõhulahtisus, iiveldus, kõhuvalu
English: Apply immediately upon removal from the protective sachet.
Estonian: Paigaldada kohe pärast kaitsekotikesest väljavõtmist.
English: Apply as directed above.
Estonian: Manustage eeltoodud juhiste kohaselt.
English: Score
Estonian: Skoor
English: The application site may be covered with clothing once Kentera has dried.
Estonian: Pärast Kentera kuivamist võib manustamiskoha rõivaga katta.
English: Anticholinergic agents may potentially alter the absorption of some concomitantly administered medicinal products due to anticholinergic effects on gastrointestinal motility.
Estonian: Antikolinergilise toime tõttu seedetrakti motiilsusele võivad antikolinergilised ained muuta mõnede samaaegselt manustatavate ravimite.
English: To apply Kentera: Step 1: Choose a spot for the patch that is:
Estonian: Valige plaastrile koht, mis on
English: Fatigue, oedema peripheral, application site papules, application site anaesthesia, application site erythema, application site irritation, application site pain, application site pustules
Estonian: Väsimus, perifeerne turse, paapulid manustamiskohal, anesteesia manustamiskohal, erüteem manustamiskohal, ärritus manustamiskohal, valu manustamiskohal, mädavillid manustamiskohal
English: Dry mouth, constipation
Estonian: Suukuivus, kõhukinnisus
English: Pruritus
Estonian: − kihelus
English: Pre-clinical data reveal no special hazard for humans based on studies for acute toxicology, repeat dose toxicity, genotoxicity, carcinogenic potential and local toxicity.
Estonian: Ägeda toksilisuse, korduvtoksilisuse, genotoksilisuse, kartsinogeensuse ja paikse toksilisuse prekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Use of oxybutynin is not recommended during breast-feeding.
Estonian: Seepärast ei ole oksübutüniini kasutamine imetamise ajal soovitatav.
English: Anticholinergic medicinal products should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.
Estonian: Kusepeetuse riski tõttu tuleb olla ettevaatlik antikolinergiliste ravimite manustamisel põie väljavoolu kliiniliselt olulise obstruktsiooniga patsientidele.
English: STORING KENTERA
Estonian: kentera geel
English: Dry eye
Estonian: − naha kuivus
English: perspiration and digestion - Problems with memory, language, or thinking abilities - A progressive neurological disease characterised by tremor of resting muscles, rigidity,
Estonian: − progresseeruv neuroloogiline haigus, millele on iseloomulik puhkeolekus lihaste treemor, jäikus,
English: Non-clinical data reveal no special hazard for humans based on studies for acute toxicity, repeat dose toxicity, genotoxicity, carcinogenicity and local toxicity.
Estonian: Ägeda toksilisuse, korduvtoksilisuse, genotoksilisuse, kartsinogeensuse ja paikse toksilisuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Headache, dizziness
Estonian: − väsimus, kurnatus
English: A 14-week, open-label treatment was available for a subset of patients who completed the double-blind period.
Estonian: 14 nädala vältel avatud ravi.
English: How to use the multidose container with metering pump:
Estonian: Kuidas mõõtepumpa kasutada
English: Step 4: Apply the second half of the patch to your skin.
Estonian: Paigaldage nahale teine pool plaastrist.
English: Innova Pharma S.p.A. Tel: +39 02 48787.1
Estonian: Tel: +39 02 48787.1
English: Common side effects: - redness or rash at the site of patch application - dry mouth - constipation - diarrhoea - upset stomach - stomach pain - headache or sleepiness - urinary tract infections - blurred vision - dizziness
Estonian: - kõhulahtisus - seedehäired - kõhuvalu - peavalu või unisus - kuseteede infektsioonid - nägemise ähmastumine - pearinglus
English: Kentera 90.7 mg/g gel oxybutynin
Estonian: Kentera 90,7 mg/g geel kotikeses Oksübutüniin
English: Urinary retention, dysuria
Estonian: Kusepeetus, düsuuria
English: Each sachet of 1 gram of gel contains 90.7 mg of oxybutynin (as 100 mg oxybutynin hydrochloride) resulting in a nominal delivery of approximately 4 mg/day.
Estonian: Iga kotike 1 grammi geeliga sisaldab 90,7 mg oksübutüniini (100 mg oksübutüniinvesinikkloriidina), millega manustatakse ligikaudu 4 mg ööpäevas.
English: perspiration and digestion; - Problems with memory, language, or thinking abilities; - A progressive neurological disease characterised by tremor of resting muscles, rigidity,
Estonian: − mälu, keeleliste võimete või mõtlemisvõime häired;
English: - Are above 65 years old - Chronic dry mouth that has resulted in periodontal disease or oral fungal infections - Nerve disorder that affects involuntary body functions including heart rate, blood pressure,
Estonian: − närvikahjustus, mis mõjutab tahtmatuid kehafunktsioone, sealhulgas südame löögisagedust,
English: Each metered dose of 1 gram of gel contains 90.7 mg of oxybutynin (as 100 mg oxybutynin hydrochloride) resulting in a nominal delivery of approximately 4 mg/day.
Estonian: Iga mõõdetud annus 1 grammi geeliga sisaldab 90,7 mg oksübutüniini (100 mg oksübutüniinvesinikkloriidina), millega manustatakse ligikaudu 4 mg ööpäevas.
English: Sun/Wed Mon/Thu Tue/Fri Wed/Sat Thu/Sun Fri/Mon Sat/Tue
Estonian: P/K E/N T/R K/L N/P R/E L/T
English: Each sachet of 1 gram of gel contains 90.7 mg of oxybutynin resulting in a nominal delivery of approximately 4 mg/day.
Estonian: Iga kotike 1 grammi geeliga sisaldab 90,7 mg oksübutüniini, millega manustatakse ligikaudu 4 mg ööpäevas.
English: Physical activity subscale
Estonian: Esinemissagedus Kõrvaltoimed
English: Each metered dose of 1 gram of gel contains 90.7 mg of oxybutynin resulting in a nominal delivery of approximately 4 mg/day.
Estonian: Iga mõõdetud annus 1 grammi geeliga sisaldab 90,7 mg oksübutüniini, millega manustatakse ligikaudu 4 mg ööpäevas.
English: Uncommon side effects - bladder infection - anxiety - confusion - nervousness - agitation - difficulty in sleeping - low blood levels of potassium which can cause muscle weakness, twitching or abnormal heart rhythm - feeling worried - sleepiness, drowsy - after taste, taste changed, abnormal sense of taste (i.e. metallic taste in mouth) - not sleeping well - shaking - eyes feel sticky, gritty - a feeling of dizziness or spinning - irregular heart beat - rapid irregular heart beat - skin is markedly red - cough - increased mucous, phlegm - loose or watery stools - feeling sick, queasy - indigestion, heartburn - throwing up - swelling of blood vessels around the anus - rash
Estonian: Aeg-ajalt esinevad kõrvaltoimeid - ülemiste hingamisteede või seeninfektsioonid - ärevus - segasusseisund - närvilisus - erutus - magamisraskused - südamepekslemine - kuumahood - seljavalu - kusepeetus - urineerimisraskused - nohu - juhuslikud vigastused
English: Talk to your doctor or pharmacist if you have any questions on the use of this medicine.
Estonian: Kui teil on lisaküsimusi selle ravimi kasutamise kohta, pidage nõu oma arsti või apteekriga.
English: Common side effects - headache - dizziness - dry mouth - constipation - itchiness - itchiness, inflammation, or pain at the application site
Estonian: Sagedad kõrvaltoimed - punetus või lööve plaastri paigaldamiskohal - suukuivus - kõhukinnisus
English: Read all of this leaflet carefully before you start using Kentera.
Estonian: Enne Kentera kasutamist lugege hoolikalt infolehte.
English: Kentera should be used with caution in patients with hepatic or renal impairment.
Estonian: Kentera kasutamisel maksa- või neerufunktsiooni kahjustusega patsientidel peab olema ettevaatlik.
English: Psychiatric disorders
Estonian: Seedetraktihäired
English: - If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Estonian: - Kui ükskõik milline kõrvaltoimetest muutub tõsiseks või kui te märkate mõnda kõrvaltoimet,
English: Palpitations
Estonian: − hallutsinatsioonid
English: Total score
Estonian: − märgatav nahapunetus
English: If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Estonian: mida selles infolehes ei ole nimetatud, palun rääkige sellest oma arstile või apteekrile.
English: Each sachet of 1 gram of gel contains 90.7 mg of oxybutynin (as hydrochloride) resulting in a nominal delivery of approximately 4 mg/day.
Estonian: Iga kotike 1 grammi geeliga sisaldab 90,7 mg oksübutüniini (vesinikkloriidina), millega manustatakse ligikaudu 4 mg ööpäevas.
English: The approved application sites for Kentera are the shaded areas shown in Figure A. These are the abdomen (stomach area), upper arms/shoulder, and thigh.
Estonian: Need on kõht (mao piirkond), õlavarred/õlad ja reied.
English: Each metered dose of 1 gram of gel contains 90.7 mg oxybutynin (as hydrochloride) resulting in a nominal delivery of approximately 4 mg/day.
Estonian: Iga mõõdetud annus 1 grammi geeliga sisaldab 90,7 mg oksübutüniini (vesinikkloriidina), millega manustatakse ligikaudu 4 mg ööpäevas.
English: Figure B:
Estonian: Partii nr:
English: Abdominal discomfort, dyspepsia
Estonian: Ebamugavustunne kõhus, düspepsia
English: Daily incontinence episodes Baseline
Estonian: Vaskulaarsed häired Aeg-ajalt
English: - Keep this leaflet.
Estonian: - Painutage plaastrit ülespidi.
English: - feeling worried - sleepiness, drowsy - after taste, taste changed, abnormal sense of taste (i.e. metallic taste in mouth) - not sleeping well - shaking - eyes feel sticky, gritty - a feeling of dizziness or spinning - irregular heart beat - rapid irregular heart beat - skin is markedly red - cough - increased mucous, phlegm - loose or watery stools - feeling sick, queasy - indigestion, heartburn - throwing up - swelling of blood vessels around the anus - rash - dry skin - itchy rash - painful or difficulty urinating - blood in urine - kidney pain - delayed or slow start of urinary flow - tiredness, exhaustion - swelling of ankles, feet or fingers - small bumps at application site - numbness at application site - redness at application site - irritation at application site - pain at application site - pus filled bumps at application site - abnormal electrocardiogram (ECG or EKG, test of heart) - change in ECG or EKG - high chloride levels in blood
Estonian: Need ravimid on eelkõige: ketokonasool, itrakonasool või flukonasool (kasutatakse seeninfektsioonide raviks); makroliidantibiootikum erütromütsiin (kasutatakse bakteriaalsete infektsioonide raviks); biperideen, levodopa või amantadiin (kasutatakse Parkinsoni tõve raviks); antihistamiinid (kasutatakse allergiate, nt heinapalaviku raviks); fenotiasiinid või klosapiin (kasutatakse vaimuhaiguste raviks); tritsüklilised antidepressandid (kasutatakse depressiooni raviks); dipüridamool (kasutatakse vere hüübimishäirete raviks); atropiin ja teised antikolinergilised ravimid (kasutatakse maohäirete, nt ärritunud soole sündroomi raviks).
English: (heart failure or renal disease) should be assessed before treatment with Kentera.
Estonian: Enne ravi alustamist Kenteraga tuleb hinnata patsienti sageda urineerimise muude põhjuste suhtes (südamepuudulikkus või neeruhaigus).
English: Paediatric population
Estonian: Seltsielu allskaala
English: Apply immediately upon removal from sachet.
Estonian: Paigaldada kohe pärast kotikesest väljavõtmist.
English: Incidence
Estonian: − neeruvalu
English: Cardiac disorders
Estonian: − südame rütmihäired
English: Hydroxypropylcellulose Sodium hydroxide (for pH-adjustment) Purified water
Estonian: 6 FARMATSEUTILISED ANDMED 6.1 Abiainete loetelu etanool (96%) glütserool hüdroksüpropüültselluloos naatriumhüdroksiid (pH reguleerimiseks) puhastatud vesi
English: Rebetol ribavirin
Estonian: Rebetol ribaviriin
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rebetol on 7 May 1999.
Estonian: Euroopa Komisjon andis Rebetoli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 7. mail 1999.
English: What measures are being taken to ensure the safe and effective use of Rebetol?
Estonian: Mis meetmed võetakse, et tagada Rebetoli ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Rebetol is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Rebetoli võimalikult ohutu kasutamine.
English: Other information about Rebetol
Estonian: Muu teave Rebetoli kohta
English: The full EPAR for Rebetol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Rebetoli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is available as capsules (200 mg) and as an oral solution (40 mg/ml).
Estonian: Seda turustatakse kapslitena (200 mg) ja suukaudse lahusena (40 mg/ml).
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom need to be adjusted for patients who experience side effects.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: It has also been studied in 1,699 adults whose disease had come back after previous treatment or whose previous treatment had failed.
Estonian: Ravimit uuriti ka 1699 täiskasvanul, kelle haigus oli pärast varasemat ravi taastunud või kelle varasem ravi oli ebaõnnestunud.
English: The CHMP decided that Rebetol's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Rebetoli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Rebetol is taken with food each day in two divided doses (morning and evening).
Estonian: Rebetoli võetakse iga päev koos toiduga, jagades annuse kahte ossa (hommikune ja õhtune annus).
English: Children above 3 years of age and adolescents who weigh less than 47 kg or who cannot swallow capsules should take the oral solution at a dose of 15 mg per kilogram body weight a day.
Estonian: Vähemalt 3-aastased lapsed ja noorukid, kes kaaluvad alla 47 kg või kes ei saa kapsleid neelata, peavad kasutama suukaudset lahust annuses 15 mg kehamassi kg kohta ööpäevas.
English: There are several other side effects of Rebetol, some of which are very common (occurring in more than 1 in 10 patients).
Estonian: Rebetoli korral võib esineda ka mitmeid muid kõrvalnähte, millest mõni on väga sage (esinenud enam kui 1 patsiendil 10st).
English: Some studies also looked at signs of improvement of the condition of the liver.
Estonian: Mõnes uuringus vaadeldi ka maksaseisundi paranemise nähte.
English: Rebetol has been studied in a total of over 6,000 adults who had not been treated before, including 328 patients with cirrhosis and 507 patients also infected with HIV.
Estonian: Rebetoli uuriti kokku üle 6000 varem ravimata täiskasvanul, sealhulgas 328 tsirroosiga patsiendil ja 507 patsiendil, kellel oli ka HIV-infektsioon.
English: Rebetol is a medicine that contains the active substance ribavirin.
Estonian: Rebetol on ravim, mis sisaldab toimeainena ribaviriini.
English: What is the risk associated with Rebetol?
Estonian: Mis riskid Rebetoliga kaasnevad?
English: Rebetol must not be used in patients with severe heart disease and blood disorders such as thalassaemia and sickle cell anaemia or in pregnant or breast-feeding women.
Estonian: Rebetoli ei tohi kasutada patsiendid, kellel on raske südamehaigus ja verehäired, näiteks talasseemia ja sirprakuline aneemia, samuti mitte raseduse ega imetamise ajal.
English: This is a summary of the European public assessment report (EPAR) for Rebetol.
Estonian: See on ravimi Rebetol Euroopa avaliku hindamisaruande kokkuvõte.
English: Rebetol has also been studied in 177 children and adolescents aged between three and 17 years who had not been treated before.
Estonian: Rebetoli uuriti samuti 177 varem ravimata 3-17-aastasel lapsel ja noorukil.
English: For more information about treatment with Rebetol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Rebetoliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Combination treatment including Rebetol was effective in around a quarter of the adults whose disease had come back after previous treatment or whose previous treatment did not work, and over half of the children and adolescents treated.
Estonian: Rebetoli sisaldav kombinatsioonravi oli efektiivne ligikaudu veerandil täiskasvanutest, kelle haigus pärast varasemat ravi taastus või kelle varasem ravi ebaõnnestus, ning üle pooltel ravitud lastest ja noorukitest.
English: The main measure of effectiveness in these studies was the number of patients who had no detectable hepatitis C virus in their blood 24 weeks after the end of the treatment and could therefore be considered to be cured.
Estonian: Uuringutes oli efektiivsuse põhinäitaja patsientide arv, kellel 24 nädalat pärast ravi lõppu ei olnud veres enam tuvastatavas koguses C-hepatiidi viirust ja keda võis seetõttu pidada terveks.
English: Rebetol is thought to interfere with the production or action of viral DNA and RNA, which are needed for viruses to survive and multiply.
Estonian: Arvatakse, et Rebetol häirib viiruse püsimiseks ja paljunemiseks vajaliku viiruse-DNA ja -RNA teket või toimet.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rebetol, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Rebetoli omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rebetol.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In children weighing between 47 and 65 kg the dose ranges from 3 to 4 capsules.
Estonian: Kehamassiga 47-65 kg laste annus on 3-4 kapslit.
English: In most of the studies, the main measure of effectiveness was the amount of virus in the blood before and after six months or a year of treatment, and at ‘follow-up', six months later.
Estonian: Enamikus uuringutest oli efektiivsuse põhinäitaja viiruse sisaldus veres enne ravi, pärast 6 kuud või 1 aasta kestnud ravi ning järelkontrolli ajal 6 kuud pärast ravi.
English: The dose of Rebetol is based on the patient's body weight, and ranges from five to six capsules a day in adults.
Estonian: Rebetoli annus põhineb patsiendi kehamassil ja on täiskasvanutel 5-6 kapslit ööpäevas.
English: Haemolytic anaemia (anaemia caused by abnormal breakdown of red blood cells) is a common side effect (seen in between 1 and 10 patients in 100), usually during the first few weeks of treatment.
Estonian: Sage kõrvalnäht on hemolüütiline aneemia (aneemia, mille tekitab erütrotsüütide (vere punaliblede) ebanormaalne lagunemine; esineb 1-10 patsiendil 100st), tavaliselt esimeste ravinädalate jooksul.
English: Rebetol on its own has no effect on eliminating the hepatitis C virus from the body.
Estonian: Ainsa ravimina kasutatav Rebetol ei kõrvalda C-hepatiidi viirust organismist.
English: In adults who had not been treated before, Rebetol in combination with interferon alfa 2b was more effective than interferon alfa 2b on its own, with 41% of the patients responding to the combination treatment and 16% to the interferon alone.
Estonian: Varem ravimata täiskasvanutel oli koos alfa-2b-interferooniga manustatud Rebetol efektiivsem kui ainult alfa-2b-interferoon: ravivastusega patsiente oli kombinatsioonravi kasutanutest 41% ja ainult interferooni kasutanutest 16%.
English: For the full list of side effects reported with Rebetol, see the package leaflet.
Estonian: Rebetoli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is Rebetol?
Estonian: Mis on Rebetol?
English: Why has Rebetol been approved?
Estonian: Miks Rebetol heaks kiideti?
English: It can also be used in previously untreated patients aged three years and over whose livers are working properly.
Estonian: Rebetoli tohib ka kasutada vähemalt 3aastastel varem ravimata patsientidel, kelle maksatalitlus on normaalne.
English: Additional data from the published literature show the positive effects of ribavirin-containing medicines when taken in different combinations, including combinations with peginterferon alfa-2a and a class of medicines known as direct acting antivirals (or DAAs).
Estonian: Avaldatud kirjandusest pärit lisateave tõendab ribaviriini sisaldavate ravimite positiivset toimet mitmesugustes ravimikombinatsioonides, sealhulgas kombinatsioonis alfa-2a-peginterferooniga ja otseselt toimivate viirusevastaste ainetega (DAA).
English: The haemolytic anaemia may affect a patient's heart function and lead to abnormal test values for substances such as uric acid and bilirubin in the blood.
Estonian: Hemolüütiline aneemia võib kahjustada patsiendi südametalitlust ja põhjustada teatud verenäitajate (nt veres sisalduva kusihappe ja bilirubiini) ebanormaalseid analüüsitulemusi.
English: In all of the studies, Rebetol was given in combination with interferon alfa-2b or peginterferon alfa-2b.
Estonian: Kõigis uuringutes kasutati Rebetoli koos alfa-2b-interferooni või alfa-2b-peginterferooniga.
English: What benefit has Rebetol shown during the studies?
Estonian: Milles seisneb uuringute põhjal Rebetoli kasulikkus?
English: A 40% increase was seen among patients who had been treated before.
Estonian: Varem ravitud patsientide seas suurenes ravile reageerinud patsientide arv ligikaudu 40% võrra.
English: The active substance in Rebetol, ribavirin, is an antiviral belonging to the class ‘nucleoside analogues'.
Estonian: Rebetoli toimeaine ribaviriin on nukleosiidianaloogide klassi kuuluv viirusevastane aine.
English: Rebetol is used in combination with other medicines to treat adults with long-term hepatitis C (a disease of the liver due to infection with the hepatitis C virus).
Estonian: Rebetoli kasutatakse koos teiste ravimitega kroonilise C-hepatiidi (C-hepatiidi viiruse nakkusest põhjustatud maksahaigus) raviks täiskasvanud patsientidel.
English: How has Rebetol been studied?
Estonian: Kuidas Rebetoli uuriti?
English: Rebetol in combination with peginterferon alfa 2b was also effective in adults with cirrhosis or HIV.
Estonian: Rebetoli ja alfa-2b-peginterferooni kombinatsioon oli efektiivne ka tsirroosiga või HIV-infektsiooniga täiskasvanutel.
English: What is Rebetol used for?
Estonian: Milleks Rebetoli kasutatakse?
English: How is Rebetol used?
Estonian: Kuidas Rebetoli kasutatakse?
English: Two main studies involving 1,503 adult patients with type 1 hepatitis C and compensated liver disease investigated the effect of ribavirin in a triple therapy combination with peginterferon alfa-2b and boceprevir.
Estonian: Kahes põhiuuringus (1503 täiskasvanud patsienti, kellel oli 1. tüüpi C-hepatiit ja kompenseeritud maksahaigus) uuriti koos alfa-2b-peginterferooni ning botsepreviiriga kasutatud ribaviriini toimet (ravi kolme preparaadiga).